×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OTLK – outlook therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OTLK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
05:29 pm
otlk
Outlook Therapeutics files to sell 21.72M shares of common stock for holders [Seeking Alpha]
Low
Report
Outlook Therapeutics files to sell 21.72M shares of common stock for holders [Seeking Alpha]
2/28
10:53 am
otlk
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]
2/28
08:05 am
otlk
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Medium
Report
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
2/24
08:16 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $33.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $33.00 to $24.00. They now have a "buy" rating on the stock.
2/19
09:00 am
otlk
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Medium
Report
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
2/18
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
2/18
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at HC Wainwright from $30.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at HC Wainwright from $30.00 to $3.00. They now have a "buy" rating on the stock.
2/14
09:35 am
otlk
https://seekingalpha.com/news/4408572-outlook-therapeutics-reports-q1-results [Seeking Alpha]
Low
Report
https://seekingalpha.com/news/4408572-outlook-therapeutics-reports-q1-results [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
3.9%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
1.6%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
-1.6%
outlook therapeutics, inc.
2/14/2025
08:05 am
otlk
outlook therapeutics, inc.
MISS
Report
1.1%
outlook therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
06:02 am
otlk
Form EFFECT Outlook Therapeutics,
Medium
Report
Form EFFECT Outlook Therapeutics,
3/28
04:44 pm
otlk
Form 424B3 Outlook Therapeutics,
Medium
Report
Form 424B3 Outlook Therapeutics,
3/14
05:00 pm
otlk
Form 8-K Outlook Therapeutics, For: Mar 11
Low
Report
Form 8-K Outlook Therapeutics, For: Mar 11
3/12
09:11 pm
otlk
Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments
Low
Report
Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments
3/12
08:56 pm
otlk
Form 4/A Outlook Therapeutics, For: Jan 17 Filed by: Sukhtian Ghiath M.
Low
Report
Form 4/A Outlook Therapeutics, For: Jan 17 Filed by: Sukhtian Ghiath M.
3/10
06:01 am
otlk
Form EFFECT Outlook Therapeutics,
Medium
Report
Form EFFECT Outlook Therapeutics,
3/7
04:21 pm
otlk
Form 424B3 Outlook Therapeutics,
Medium
Report
Form 424B3 Outlook Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/15
Form 10-Q Outlook Therapeutics, For: Mar 31
62.8%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
12/31 Form 4 Outlook Therapeutics, For: Dec 31 Filed by: Pillai Arun Kumar 48.6%
2/24 Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market 20.0%
12/3 Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 16.9%
7/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 14.8%
12/30 Form 4 Outlook Therapeutics, For: Dec 23 Filed by: Pillai Arun Kumar 13.5%
12/23 Form 8-K Outlook Therapeutics, For: Dec 20 11.3%
5/20 Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up [Seeking Alpha] 11.1%
4/15 Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit 9.2%
9/11 Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference 7.3%
TOP News Decliners
12/23
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
-50.0%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
1/28 Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 -15.0%
12/3 Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha] -14.0%
8/27 Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference -12.6%
5/15 Q2/2019 3/31/2019 EPS -0.580 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
5/17 Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days [MarketWatch] -9.1%
9/18 Outlook Therapeutics, Inc. (NASDAQ: OTLK) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.0%
6/3 Form S-3 Outlook Therapeutics, -7.3%
2/24 Form 424B5 Outlook Therapeutics, -7.3%
6/14 Form 8-K Outlook Therapeutics, For: Jun 11 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: